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ABSTRACT 
This study reports on 24 Myelomeningocoeles (MMC) repaired at Chris Hani 
Baragwanath Hospital by a single surgeon. 
Mean gestation was 38.13 weeks, most MMCs were in the lumbosacral region and 
mean MMC surface area was 19.4cm2.  Cerebrospinal Fluid (CSF) leak at birth was 
present in 50%, lower-limb neurology in 71%, lower cranial nerve dysfunction in 13% 
and hydrocephalus in 54%.  Clubfoot was present in 71%, congenital hip dysplasia 
in 24%, neurogenic bladder in 82% and cutaneous abnormalities in 12%. 
Mean time from birth to MMC repair was 13.6 days, 46% of infants had 
ventriculoperitoneal shunt insertion and latex allergy was absent. 
Complication wise, wound dehiscence arose in 21%, CSF leak in 12.5% and 
infection in 25%. Neonates with CSF leak subsequently developed both wound 
dehiscence and CSF infection. 
Maternal HIV prevalence within the series was 28% and there was potential 
correlation between CSF infection and birth to a positive mother. 
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1. INTRODUCTION 
Myelomeningocoele (MMC) is a central nervous system (CNS) malformation that 
belongs to the group of anomalies that encompass spinal dysraphism.1 Following 
congenital heart anomalies, spinal dysraphism forms the second most frequent 
group of birth malformations.2 
 
 1.1 Epidemiology  
Incidence of spinal dysraphism varies greatly according to geographical location 
and varies between 1 per 200 live births to 1 per 10,000 live births.3 Aetiology is 
largely multi-factorial with genetic and environmental interplay.  Mothers that 
have conceived a child with an MMC have 3% risk in subsequent pregnancies and 
mothers that have conceived two children with an MMC have a 10% subsequent 
risk.4  Folate deficiency is a well-known cause for MMC development and has 
received considerable attention as preventative treatment – see section 1.5.1.5  
Anti-epileptic medication increases the risk of neural tube defects (NTDs), with 
sodium valproate increasing the risk 20-fold.6  Other factors thought to increase the 
risk of MMCs include diabetes, obesity, heat exposure, fever, alcohol, tobacco 
and illicit substance abuse.4 
 
 1.2 Pathology 
  1.2.1 Neural Tube Development 
The neural tube is the embryonic scaffold upon which the future CNS develops. 
Development of the neural tube is a post-gastrulation event, at which point the 
embryonic disc is composed of ectoderm, mesoderm and endoderm and is 
surrounded by the amniotic cavity dorsally and yolk sac ventrally.  On days 16-17 
post-conception, the notochord in the midline of the embryonic mesoderm 
develops as a solid structure.7,8  The notochord secretes nogin, chordin and 
folliculostatin.  These molecules act as inhibitors to Bone Morphogenic Protein 
(BMP) – 4 and block the binding of BMP-4 to its receptor on the ectoderm.1,8   By 
day 20 post-conception, this process induces the dorsally overlying ectoderm to 
fold inwards and form the neural groove centrally and plates laterally.  This marks 
commencement of Primary Neurulation – see Figure 1.1.7,8   
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Following initiation of Primary Neurulation, the lips of the neural folds disjoin to form 
the neural crest and then proceed to unite with their contralateral counterpart to 
form the neural tube.  Once formed, the neural tube lies deep to overlying 
ectoderm and mesodermal derived vertebral arches encircle the neural tube to 
form the future lamina and spinous processes.  In a zipper-like manner, this process 
proceeds along the cephalo-caudal axis of the embryo until only cranial and 
caudal neuropores are present.  These neuropores form transient connections 
between the neural tube lumen and the amniotic cavity.  Eventually, the cranial 
neuropore closes on day 25, its remnant the lamina terminalis and the caudal 
neuropore closes on day 28, its remnant at lumbar spine level one (L1).  Enclosure 
of the neural tube marks completion of Primary Neurulation.7,8 
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Figure 1.1: Scanning electron micrograph depicting primary neurulation in a chick 
embryo.  Days in top left corner indicative of days post-conception in a human 
equivalent.  A Neural folds commence folding and forming neural groove.  B 
Progression of neural groove folding.  C Completion of neural tube formation.53 
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Secondary Neurulation forms the part of the spinal cord below S2 and includes 
lower sacral spinal segments, conus medularis and the cauda equina – see Figure 
1.2.  It is composed of two stages: Tail bud canalisation of the medullary cord, 
which occurs between days 28-48 and regression, which occurs from day 48 up 
until birth.  During tail bud canalisation the tail bud derives from a primitive streak 
remnant, which contains an undifferentiated cell mass under the ectoderm.  This 
mass forms vacuoles that coalesce to form the terminal ventricle and subsequently 
distal neural tube.  Following formation, the distal neural tube ascends to fuse with 
the neural tube formed by Primary Neurulation. 7,8 
In summation, Primary Neurulation forms the CNS from telencephalon to L1 and 
Secondary Neurulation forms the CNS from L1 to the cauda equina. 7,8 
 
 
 
 
Figure 1.2: Diagrammatic representation of secondary neurulation showing   tail 
bud canalisation.54 
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  1.2.2 Embryopathology of Spinal Dysraphism and MMCs 
Spinal dysraphism is a congenital anomaly that arises from defective neural arch 
formation and ensuing herniation of meninges, neural elements or a combination 
of the two.  Depending on the presence of covering skin and the contents of the 
herniated sac there are a variety of clinical manifestations.  In broad terms, spinal 
dysraphism can be subdivided into closed spinal dysraphism and open spinal 
dysraphism.4,9   
In closed spinal dysraphism, the neural tube has disjoined from the ectoderm and 
an intact layer of skin lies between the environment and the underlying anomaly.  
It is often associated with overlying cutaneous manifestations such as naevi, 
hypertrichosis, skin dimples or haemangiomas.  Clinical manifestations of closed 
spinal dysraphism based on this definition include unfused spinous processes, 
intradural lipoma, filum terminale fibrolipoma, filum terminale thickening and 
shortening, myelocystocoele, lipomyelomeningocoele, meningocoele and dermal 
sinus tracts with or without epidermoids and dermoids.4,9 
In the open variety of dysraphism there is failure of disjunction between the 
ectoderm and neural folds.  This leads to exposed meninges or neural elements 
and is clinically confined to open MMCs The remainder of this discussion will focus 
on MMCs.4,9 
Embryologically, MMC is the manifestation of aberrant primary spinal neurulation.  
The caudal neuropore fails to disjoin from the ectoderm leaving the neural 
placode exposed.  This prevents mesodermal derived vertebral arches from 
migrating dorsally and enclosing the future spinal cord.  Consequently, the 
placode is exposed to amniotic fluid, which hinders neurodevelopment by causing 
neuronal apoptosis and deranged axonal connections.  Ultimately, there is a 
malformed spinal cord and an MMC presentation at birth.4,9 
 
  1.2.3 Molecular Biology of MMCs 
Honing in on candidate genes responsible for MMC formation has been a difficult 
task.  This is likely the result of a multifactorial interplay between multiple candidate 
genes and environmental factors.1  Multiple strategies, including genome-wide 
association, whole exome sequencing and whole genome sequencing have 
been employed in the endeavour to find responsible genes.  These efforts have 
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yielded more than 200 genes that are implicated in MMC formation.10  The 
function of these genes includes apoptosis, cell cycle signalling, cytoskeletal 
architecture, glucose metabolism, methylation, to name a few.10  Despite this 
complexity, there are several signalling pathways that have received particular 
attention in regard to MMC formation.  These signalling pathways are the planar 
cell polarity signalling pathway, sonic hedgehog pathway, BMP pathway, 
grainyhead-like gene pathway and retinoid signalling pathway.1 
 
 1.3 Clinical Presentation 
Neonates born with MMCs are prone to numerous developmental abnormalities.  
Neurologically, neonates may have partial motor and sensory function below the 
lesion or have complete spinal cord paralysis.4  This is associated with neurogenic 
bladder prevalence of up to 60%.11  Hydrocephalus develops in 80-90% of 
neonates born with MMCs and presents with associated symptoms and signs of 
macrocephaly and increased intracranial pressure.12  Imaging wise, apart from 
features of hydrocephalus there is increased prevalence of colpocephaly – 
enlargement of the occipital horns.12  The Chiari Type II malformation is also 
common in neonates with MMCs and presents with opisthotonos, stridor, apnoea 
and even sudden death.12  In later life, during growth spurts, children with MMCs 
may present with new onset neurological defecit secondary to a tethered spinal 
cord.5  Eighty precent of children with MMCs attain a normal intelligence quotient 
(IQ) score; however this may be adversely affected by early onset meningitis.13,14 
Apart from the CNS, numerous other organ systems may be affected in children 
with MMCs.  Urological pathology includes horseshoe kidneys, hydronephrosis and 
renal failure secondary to the effects of a neurogenic bladder.  Faecal 
incontinence may arise.  The musculoskeletal system may be affected secondary 
to kyphosis or scoliosis, congenital hip dysplasia and clubfoot.  Cutaneous lesions 
may also arise with various forms of naevi or hairy tufts around the lumbar region.  
Finally, neonates with MMCs may present with anal sphincter dysfunction or rectal 
prolapse and are commonly affected by latex allergy.1,4,7 
Post-delivery, neonates with MMCs have a high risk of meningitis secondary to 
bacterial colonisation of their exposed neural placode.  Meningitis in these 
neonates may progress to ventriculitis with ensuing cortical injury and a high 
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degree of morbidity and mortality.1,4,7  In fact, not treating MMCs with surgical 
repair has a documented survival rate of 10-12% largely due to infective 
sequelae.15 
 
 1.4 Prenatal Screening and Diagnosis 
The potentially devastating consequences of MMCs and their associated 
conditions has led to active screening protocols. 
Maternal serum alpha-fetoprotein is detectable from week 12 of pregnancy and 
steadily increases up to week 32.  At weeks 15-20, if serum alpha-fetoprotein is 
twice the normal amount, the risk for a NTD increases from baseline by 224-fold.  
Sensitivity for spina bifida is 91%, whereas sensitivity for anencephaly is 100%. 16 
Amniocentesis, to quantify amniotic alpha-fetoprotein, is also utilised.  It peaks 
between 13-15 weeks of gestation and is recommended if a mother has had a 
previous child with a NTD or there is any uncertainty from the serum alpha-
fetoprotein measurements and prenatal ultrasound.  In addition to alpha-
fetoprotein, acetylcholine esterase can also be measured as a NTD marker.  
Combining alpha-fetoprotein and acetylcholine esterase measurements as a 
screening tool for spina bifida achieves a sensitivity of 99% with a false-positive rate 
of 0.34%.  Unfortunately, amniocentesis carries a miscarriage risk of up to 6%.17 
Second-trimester foetal anatomic survey with prenatal ultrasound imaging has 
sensitivity of 98% in detecting spina bifida.18  The advantage of prenatal ultrasound 
is its non-invasive nature and ability to detect associated anomalies such as 
hydrocephalus, clubfoot, Chiari malformation and kyphoscoliosis.  With 
appropriate windows in the axial, coronal and sagittal planes the spine is 
completely assessed and a potential MMC can be fully characterised.  
Importantly, detailed assessment of the lower limbs and characterisation of flexion 
and extension motions at the hip, knee and ankle joints can provide crucial 
information that predicts neurological compromise.  This information can be vital 
for pregnancy termination counselling and postnatal care for the future fetus.18 
Foetal magnetic resonance imaging (MRI) has become an established adjunct to 
foetal ultrasound.19  The development of heavily T2-weighted MRI sequences that 
can be acquired in very short acquisition times – half-Fourier single-shot turbo spin-
echo (HASTE) sequence – has increased the scope for foetal MRI in MMC 
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assessment.  It is particularly useful in settings such as maternal obesity, 
oligohydraminos and suboptimal foetal positioning where ultrasound evaluation 
may be limited.  Although safe, foetal MRI is best considered following the first 
trimester to avoid the theoretical risk for teratogenesis and improve the quality of 
images with a larger fetus.19   
 
 1.5 MMC Management 
  1.5.1 Pre-conception Management 
The mainstay of MMC prevention is folic acid supplementation.20  Folic acid 
administration during pregnancy was established by two randomised control trials 
in the early nineties.  The Medical Research Council Vitamin Study Group 
demonstrated that administration of 4mg/day of folic acid in families with a history 
of previous NTDs had a 72% protective effect.21  Czeizel et al. went on to 
demonstrate that 0.8mg/day of folic acid supplementation introduced prior to 
conception reduced the incidence of NTDs.22  These two studies firmly established 
pre-conception folic acid administration in order to reduce incidence of NTDs and 
led to worldwide policies to fortify flour with folic acid.  In fact, countries that 
established folic acid fortification had a marked reduction in NTD incidence.20 
 
  1.5.2 Post-Delivery Management 
When MMCs have been detected prenatally, planned caesarean section delivery 
is advised.  This ensures that the cerebrospinal fluid (CSF) filled MMC is not injured 
along the birth canal, which may lead to a CSF leak and subsequent infection.   
Following birth, the MMC should be covered with a non-adhesive silicone based 
dressing, layered on top with a piece of sterile gauze and then sealed with a 
plastic wrap.  This prevents urine and faecal contamination. The dressing should be 
changed daily until surgery and the neonate nursed prone or on its side.  Some 
centres advocate pre-operative antibiotic cover and if very early surgery is 
planned, some centres do not initiate oral feeds in order to prevent faeces and 
the potential for contamination.23 
The first 24 hours of life are used to stabilise the neonate and assess for any other 
associated abnormalities, some of which, may have been identified prenatally.  
Pending the neonate is stable, blood is cross-matched and surgery for repair of the 
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MMC is planned within 48-72 hours of birth.  This strategy has been developed to 
decrease the risk of meningitis secondary to CSF infection.23   Controversy exists in 
regard to the timing of CSF diversion.23,24  There are proponents of a simultaneous 
MMC repair and ventriculoperitoneal (VP) shunt insertion.24  However, others 
advocate MMC repair followed by watchful waiting.  If hydrocephalus arises a VP 
shunt is inserted; however for the 20% of patients that do not develop 
hydrocephalus, VP shunting and potential shunt complications are avoided.23  
Interestingly, Warf has demonstrated that endoscopic third ventriculostomy 
combined with choroid plexus cauterisation can treat 76% of infants with 
hydrocephalus secondary to MMC without the need for further surgery.25  This can 
drastically reduce the requirement for shunting.25 
Post MMC repair, multidisciplinary care is essential.4  Urology wise, the neonate will 
require a renal tract ultrasound, urodynamic studies and a vesicourethrogram.11  
Parents will need to be taught how to perform intermittent clean catheterisation 
and anti-muscurinic agents are commenced.11  Orthopaedic wise, input is 
required if the neonate has clubfoot or congenital hip dysplasia.4  Finally, 
psychological support for the family is pertinent.26   
 
  1.5.3 Surgical Techniques for MMC repair 
As MMC repair is neonatal surgery, special attention must be given to preventing 
hypothermia.  It is recommended that theatre is kept at 28 degrees Celsius and 
that the neonate is kept warm with warming pads, cotton rolls, aluminium foil to 
cover the head and limbs, occlusive plastic sheets to cover the non-operative site 
and warm saline.27 The neonate is proned and attention paid to pressure points 
and maintaining a free abdomen.  Anaesthesia wise, special attention must also 
be given to monitoring intra-operative haematocrit and serum glucose.27 
Surgical repair of MMCs requires precise dissection, meticulous haemostasis, 
minimal electrocautery and repair under magnification.23  The junction of the 
neural placode with the surrounding dysplastic skin is defined and the narrow 
groove that bisects the placode in the midline identified.  This represents the 
primitive ventral sulcus and is continuous with the central canal of the closed spinal 
cord proximal to the placode.  An incision is made along the junction of the 
placode with the dysplastic skin and care is taken to excise remnants of dysplastic 
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skin along the junction as it could lead to future inclusion dermoids.  Once the 
placode is free and the proximal junction of the placode with the normal spinal 
cord defined, the placode is reconstucted into a neural tube with a non-
absorbable 6-0 monofilament suture.  Following, the dura is dissected free from the 
MMC cavity and then closed in a watertight fashion with a non-absorbable 5-0 
monofilament suture.  The repair is tested for CSF leaks with a Valsalva manoeuvre.  
The subcutaneous tissue is undermined widely and depending on the available 
subcutaneous tissue one or two further layers are closed with a 4/0 absorbable 
suture.  Finally, residual dysplastic skin is excised, dog-ears are neatened and skin is 
closed with 5-0 nylon interrupted sutures.  The wound is dressed with an occlusive 
dressing and the neonate is nursed prone for seven to ten days until the skin has 
healed and sutures are removed.  Large dorsal defects following MMC repair 
require closure with local flaps – see Figure 1.3.23 
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Figure 1.3: A Neonate with typical MMC from the series. B MMC placode and surrounding membrane with dysplastic skin.  C 
Placode freed from surrounding dysplastic skin.  D Reconstruction of placode into neural tube.  E Dura was dissected off 
MMC cavity and closed primarily over the reconstructed placode.  F Primary closure of MMC skin defect. G Author elected 
to utilise a Limberg flap as defect was large.  NOTE: consent was obtained from parents for the presented photographs. 
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Of note, Albright et al. reported on distal cordectomy, whereby the placode is not 
reconstructed but rather excised at its proximal end, as an option for MMC 
repair.28  They reported that the majority of infants treated with distal cordectomy 
retained preoperative motor function after surgery and proposed this technique as 
a viable option for the treatment of MMCs.28  Distal cordectomy may be a 
procedure of choice in the setting of delayed MMC presentations.28 
 
  1.5.4 Long-Term Management 
As children born with MMCs have multisystem involvement and are often disabled, 
on-going multidisciplinary care is essential.29  It is estimated that the lifetime 
medical and non-medical costs of an individual with a NTD are $560,000 United 
States Dollars.30 
Following discharge, neonates with MMCs are best followed-up under dedicated 
clinics that bring together all specialists involved in their care.4,26,29  From a 
Neurosurgical standpoint, close monitoring is required for children with shunts and 
to anticipate symptoms related to a tethered cord syndrome that will require 
future release.5  Urology wise, patients need to be followed-up for urinary catheter 
management and advised on a future bladder augmentation procedure.11,29  
Orthopaedic input is generally ongoing in the early years in the setting of clubfoot 
and congenital hip dysplasia.29  Finally, psychological support is very important; 
initially for the parents and then for the child with the MMC, as they grow older.26 
Despite disability, a considerable amount of neonates born with MMCs progress to 
become contributing members of society.5  Some 82% of adults achieve 
independence in activities of daily living, 30% attend or finish University and 32% 
are gainfully employed.5   
 
 1.6 Prenatal MMC Repair:  The MOMS Trial 
Advancement in the field of foetal surgery inspired considerable interest in 
prenatal repair of MMCs.31  Proponents of in utero repair advocated the two-hit 
hypothesis whereby the first hit comes about from failure of neural tube closure 
and the second hit comes about secondary to exposure of a normal spinal cord to 
amniotic fluid, direct trauma and hydrodynamic pressure.  Based on this two-hit 
hypothesis, proponents argued that early foetal surgery ameliorates the second hit 
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by covering the spinal cord and protecting it from the effects of progressive 
exposure.31 
On this background, the Management of Myelomeningocoele Study (MOMS) was 
initiated in 2003.32  MOMS was a multicenter prospective randomised clinical trial 
comparing treatment outcomes between prenatally and postnatally repaired 
MMCs.  Foetal surgery was performed at Vanderbilt University, University California 
San Francisco and at the Children’s Hospital of Philadelphia.  The planned sample 
size was 200 patients but the study was stopped early in 2010 after 183 patients by 
the Data Safety and Monitoring Board.32   
The MOMS study concluded that prenatal intrauterine repair of MMCs between 
weeks 19-25 of gestation was superior to standard postnatal Neurosurgical repair in 
terms of long-term outcomes.32  At one year of age following foetal surgery 40% of 
prenatally repaired MMCs required a VP shunt compared to 82% of postnatally 
repaired MMCs.  At 30 months, 42% of prenatally repaired MMCs were walking 
independently compared to only 21% of the postnatally repaired group.  Finally, 
hindbrain herniation was significantly reduced in the prenatally repaired group, 
potentially protecting this group from the severe sequelae of an Arnold Chiari Type 
II malformation.32 
The MOMS trial also elucidated the risks in relation to foetal surgery for MMCs.32  In 
the prenatally repaired group there was an increased risk of spontaneous rupture 
of membranes, oligohydraminos, preterm delivery and uterine thinning or 
dehiscence.  These factors considered, the potential benefits obtained with 
prenatal surgery still led the investigators to conclude that prenatal repair is 
beneficial in the long-term.32 
Despite these important findings, it must be appreciated that foetal surgery is 
resource intense and requires considerable expertise in surgical, foetal and 
maternal care.31,32  Costs involved for the setup and care are considerable, which 
in less developed settings make the procedure, to a large extent, prohibitive.31,32 
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 1.7 MMC Repair Outcomes and Complications 
  1.7.1 Large Surgical Series 
Survival rate for MMCs born before the nineteen sixties was between 10-12%.15  
Treatment was typically postponed until the age of two and survival was based on 
a self-selected cohort.  Antibiotic availability, development of the VP shunt and 
neuropathic bladder management drastically improved survival in neonates born 
with MMCs and led to a paradigm shift that advocated MMC repair within 48-72 
hours.15  In fact, Pinto et al. demonstrated that repair immediately after birth, 
termed “time zero repair” yields even better long-term results.33  Based on this 
paradigm shift, at least 75% of children born with MMCs can be expected to reach 
early adulthood.15 
Notably, series by Lorber analysing post-operative results in 524 MMC cases, 
McLone analysing 100 consecutive cases and Mirzai et al. analysing 190 MMC 
patients have provided important baseline information on the condition and 
surgical outcomes following open MMC repair.34-36 
 
  1.7.2 Complications 
Extracting from the aforementioned studies, postoperative mortality following 
MMC repair is low.  However, morbidity post repair can be significant and to a 
large extent is preventable with meticulous preoperative planning.37   
 
   1.7.2.1 Wound Dehiscence 
Wound Dehiscence is a common complication post MMC repair.38,39  Poor 
nutritional status and unfavourable local wound factors are responsible for this 
adverse outcome.38 
Nutritionally these neonates are at a disadvantage secondary to low birth weights, 
negative nitrogen balance, hypoalbuminaemia and low lymphocyte counts. 
These factors can lead to a catabolic state and recovery from this state does not 
occur until one-month post MMC repair. Compounded on this are potential 
feeding problems secondary to hydrocephalus, Arnold Chiari malformation and 
postoperative ileus.  As a whole, the aforementioned factors may lead to poor 
post-operative wound healing, which intern increases the risk of wound 
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dehiscence.  As such, proactive nutritional management of neonates born with 
MMCs is essential.38   
Local factors are also extremely important predictors for wound dehiscence.  
Large skin defects lead to higher tension on the suture line of MMC repairs.  This 
can decrease cutaneous blood supply and lead to necrotic edges with 
subsequent dehiscence.  In a similar manner, Kyphosis can also compromise blood 
supply to the surgical wound by stretching the wound posteriorly in the ventral-
dorsal plane.  Importantly, when wide subcutaneous undermining or local flaps are 
required dehiscence can ensue secondary to skin flap necrosis. This can be 
challenging to address.38 
 
   1.7.2.3 CSF Leak 
Following watertight closure of the dural sac there is a post-operative risk of CSF 
leak.  There is wide range of reported CSF leakage rates in the literature, with 
several large series not quantifying the phenomenon.37,38  Chand et al. reported a 
CSF leak rate of 8.1% and Fazal et al. had a CSF leak rate of 12.72%. 39,40 Leakage 
of CSF through the surgical wound increases the risk for wound dehiscence as well 
as meningitis with its accompanying complications.  As a result, it must be 
identified early and managed aggressively.  In addressing the potential for this 
complication, meticulous surgical technique, testing the repair with a Valsalva 
manoeuvre, multilayered closure and CSF diversion in the setting of hydrocephalus 
are essential practises.23,37   
 
   1.7.2.4 Infection 
MMC infection rates, depending on the series, are quoted as between 1 to 
37%.23,37,41,42  Infections can be subdivided into extradural and intradural infections.  
Extradural infection arises secondary to contamination of the wound by skin 
commensals, faeces or urine.  Clinically, extradural infection is suspected when 
erythema arises around the wound and the infection is treated aggressively with 
antibiotics.  Intradural infections are more serious and tend to progress to 
meningitis and subsequently ventriculitis.  Gram-negative enteric pathogens tend 
to be the source of most CSF infections in this setting.  Intradural infections require 
prompt use of antibiotics and frequent CSF cultures in order to obtain antibiotic 
	 16 
sensitivities.37  CSF infection in the setting of MMCs can have devastating 
consequences.  As aforementioned, McLone et al. firmly established, 
hydrocephalus independent, deterioration of IQ scores in neonates that suffered 
from meningitis or ventriculitis.14 
Based on the severe consequences of CNS infection for neonates born with 
MMCs, prophylaxis with broad-spectrum antibiotics is commonly employed.43  By 
employing this strategy, ventriculitis risk is reduced and neonates have better 
outcomes.43  
Early surgery is also crucial in reducing the risk of CNS infection.  Incidence of 
ventriculitis is at 7% with early closure as opposed to 37% with closure beyond 72 
hours.23  These findings, further stress the importance of early closure. 
 
   1.7.2.4 Other Complications 
Less frequent post-operative complications following MMC repair also occur.  Post-
operative ileus may occur, particularly in the setting of large defects requiring 
widespread undermining and use of myocutaneous flaps.  This complication is 
usually self-limiting.  Pneumothorax may arise following deep dissection of latissimus 
dorsi in the thoracic region; again, this is more frequent following closure of large 
defects.  Finally, necrotising enterocolitis is slightly more frequent post MMC 
repair.37 
 
 1.8 MMC Literature in South Africa 
  1.8.1 Epidemiological Studies in South Africa 
Addressing the needs of children born with MMCs in South Africa and providing 
care for these children in a multidisciplinary setting has been instituted as early as 
the 1960s.29  An epidemiological study in Cape Town has documented the 
incidence of NTDs between 0.63 – 1.74 per 1000 births, with prevalence highest in 
the local Caucasian population.44  In Gauteng, a study looking at NTD recurrence 
risk, identified a 2.28% recurrence risk following one child with a NTD and a 4.16% 
risk following birth of two affected children.45  These rates are lower than the 
international literature. Lebese et al. reported on the National Congenital Disorder 
Surveillance System, analysing data from 2006-2014.46  During this time period there 
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were 787 NTDs reported.  However, the authors commented that reporting to the 
surveillance system is erratic and inadequate.46  
 
  1.8.2 Prenatal Prevention and Diagnosis in South Africa 
In 2003, South Africa initiated folic acid fortification of staple foods.47  Following 
implementation of this program, incidence of NTDs decreased from 1.41 to 0.98 
per 1000 births.  Spina Bifida specifically, declined by 41.6%.47 
For the most part, MMC diagnosis in South Africa is made postnatally.29  This is 
attributed to low maternal awareness and uptake of measures that prevent NTDs.  
In a study sampling a sub-Saharan population of mothers that had neonates with 
NTDs, only 18.8% were aware that folic acid reduced the incidence of NTDs and 
only 10.7% had dietary multivitamin supplementation.48  Of the defects analysed in 
this study, only 17.8% were diagnosed prenatally.  Interestingly, 23% of mothers 
reported that they might have requested for termination of the pregnancy.48  In a 
similar manner, Sayed et al. demonstrated in a cohort of pregnant women in 
Cape Town that only 20.6% had heard of folic acid and only 11.1% related it to 
birth defects.49 Clearly, these studies demonstrate that more needs to be 
achieved from a public health perspective in relation to NTD prevention in sub-
Saharan Africa. 
 
  1.8.3 Surgical MMC Repair Series in South Africa 
To the author’s knowledge, there is no published surgical series from South Africa 
analysing post-operative MMC repair results.  Narotam et al. from Durban, 
published a 22.4% incidence of wound complications and 14.8% incidence of 
sepsis post NTD repair.50  These rates were extracted from a broader study 
analysing operative sepsis in Neurosurgery.  
 
  1.8.4 Long-term Follow-up Post MMC Repair in South Africa 
Follow-up of children born with MMCs is important in analysing the success of local 
infrastructure in addressing the needs of these children. Buccimazza et al. 
followed-up a cohort of children born with MMCs from Cape Town and compared 
them to children born with MMCs in rural areas.51  By analysing the general 
development quotient at 5 years, they found that there was no significant 
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difference in outcomes between children from urban areas and the rural areas.  
Caesarean section delivery and early MMC closure led to a higher general 
development quotient, whereas CNS infection and placement of more than one 
shunt led to a lower quotient.51 
 
 1.9 MMCs and Human Immunodeficiency Virus Infection 
MMC literature in relation to human immunodeficiency virus (HIV) infection is 
limited.  There is some literature to support that maternal exposure to the anti-
retroviral drug, efavirenz, increases the incidence of NTDs.52 Aside from this, there is 
a paucity of literature.  To the author’s knowledge, there are no studies that have 
investigated post-operative MMC repair results in neonates born to mothers with 
HIV infection. 
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 1.10 Study Aims and Objectives 
It is evident from the literature that MMCs affect a considerable population at 
great human and financial cost.  As prenatal diagnosis in South Africa remains a 
challenge, it is important to understand factors that lead to good post-operative 
results following MMC repair. This is essential to improve both neonatal care and to 
also save on health care costs by reducing patient days in hospital.  To address this 
need, a retrospective study of all the MMCs that were repaired by that author (Dr 
Christos Profyris) at Chris Hani Baragwanath Hospital (CHBH), from 1 January 2014 
to 1 August 2015 was undertaken.  The rational behind investigating patients 
repaired by a single surgeon is to compare patient outcomes following a 
standardised and identical repair technique.   
To the author’s knowledge, there are no published surgical series from South Africa 
analysing post-operative MMC repair results.  This is important, as unique 
challenges faced in a South African context may influence outcomes. 
Furthermore, there are no studies that have investigated post-operative MMC 
repair results in neonates born to mothers with HIV infection.  Upon this 
background, the present study aims to contribute to the MMC literature by:  
1. Describing base-line clinical characteristics of neonates born with MMCs at 
CHBH or referred to CHBH 
2. Analysing surgical outcomes following MMC repair by a single surgeon at 
CHBH 
3. Identifying factors that may influence post-operative complications related 
to MMC surgery at CHBH 
4. Investigating if maternal HIV infection leads to different outcomes in 
neonates born with MMCs 
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2. METHODS 
2.1 Study Design 
This study was structured as a retrospective clinical audit of all MMCs repaired at 
Chris Hani Baragwanath Hospital by the author from 1 January 2014 to 1 August 
2015.  During this period, the author repaired all the MMCs referred to the 
Department of Neurological Surgery at CHBH. 
All MMCs were repaired with the technique described in Section 1.5.3 and VP 
shunting was undertaken if the neonate developed signs and symptoms of 
hydrocephalus. 
 
2.2 Sample 
All patients with MMCs that were either born at CHBH or referred to CHBH from 
peripheral hospitals and operated upon by the author were included in the study. 
Pending the above criteria were met, there were no exclusionary criteria.   
Prior to this series the author had performed a further fifteen MMC repairs and had 
been trained by a consultant to perform the procedure independently.  The 
current series of cases was performed by the author as the primary surgeon.   
 
2.3 Data Collection 
Following review of the author’s surgical logbook during the period 1 January 2014 
to 1 August 2015, suitable patients for the study were identified.  Hospital files of the 
identified patients were collected from the Division of Neonatology at CHBH.  
Relevant data was collected from both the author’s logbook and the collected 
hospital files.  
Data was recorded on a data collection sheet – see Appendix A – and then 
recorded onto a Microsoft Excel 2010 spread sheet.  Data recorded and 
presented includes demographic details (gestation period, gender and referral 
route), birthing details (mode of delivery, birth weight, length, head circumference 
and Appearance, Pulse, Grimace, Activity and Respiration (APGAR) scores), pre-
operative status (MMC spinal region, MMC surface area, pre-operative CSF leak 
and kyphosis), neurological abnormalities (lower limb weakness, clinical aspiration 
or dysphagia, Chiari Type II malformation, and hydrocephalus), non-neurological 
abnormalities (clubfoot, congenital hip dysplasia, neurogenic bladder and 
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cutaneous abnormalities), timing to MMC repair, operative parameters (utilisation 
of flap for closure, pre and post operative haemoglobin, blood transfusion volume 
and post-operative intensive care unit admission), post operative course (VP shunt 
insertion, external ventricular drain (EVD) insertion and latex allergy),  post-
operative complications (CSF leak, wound dehiscence and infection) and 
maternal parameters (HIV status and antiepileptic drug use during pregnancy). 
 
2.4 Data Analysis 
Statistical analysis was undertaken using the GraphPad Prism software package.  
Descriptive statistics consisting of mean and standard deviation were calculated 
for birth weight, length, head circumference, APGAR score, MMC surface area, 
timing to MMC repair, pre and post operative haemoglobin, and blood transfusion 
volume.	Absolute numbers expressed as proportions were calculated for gender, 
referral route, mode of delivery, MMC spinal region, pre-operative CSF leak, 
kyphosis, lower limb weakness, clinical aspiration or dysphagia, Chiari Type II 
malformation, hydrocephalus, clubfoot, congenital hip dysplasia, neurogenic 
bladder, cutaneous abnormalities, utilisation of flap for closure, post-operative 
intensive care unit admission, VP shunt insertion, EVD insertion, latex allergy, CSF 
leak, wound dehiscence, infection, maternal HIV status and maternal antiepileptic 
use during pregnancy. 
Cross tabulation between variables of interest was performed.  Association 
between continuous data variables was tested with an unpaired student t test.  
Categorical data variables had a low frequency of events and as such, a Fischer’s 
exact test was used to assess statistical significance.  Statistical significance was 
considered significant when a p-value was less than 0.05. 
 
2.5 Ethics 
This study was approved by the Human Research Ethics Committee (Medical) at 
the University of the Witwatersrand with Clearance Certificate Number M151101 – 
see Appendix B.  Informed consent was not required as data was acquired from 
existing hospital files and no interaction with patients occurred. All identifying 
information such as names and hospital numbers were removed from the data 
sheet and only a study number was used.  
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3. RESULTS 
 3.1 Records Reviewed 
A total of 24 patients were identified that had their MMC repaired by the author at 
Chris Hani Baragwanath Hospital during the period of 1 January 2014 to 1 August 
2015.  Their medical records were obtained and reviewed. 
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 3.2 Demographic and Birthing Details 
Demographic data and birthing details pertaining to the study population are 
summarised in Table 3.1.   
Gestational period ranged from 35 weeks to 40 weeks.  Delivery wise, 6 of the 
infants were recorded as being in breech position and there was one set of twins, 
whereby only one of the infants was affected by an MMC.  The lightest neonate 
was 2,300 grams and the heaviest 3,600 grams.  Neonate length ranged from 45 to 
50 centimetres and head circumference ranged from 31 to 37 centimetres.  The 
lowest APGAR score at 1 minute was 5 and the lowest APGAR score at 5 minutes 
was 8. 
 
Table 3.1: Demographic and Birthing Details  
VARIABLE RESULT 
MEAN GESTATION PERIOD (weeks) 38.13 +/- 1.6 (n=15) 
GENDER  
Male 66.67% (n=16) 
Female 33.33% (n=8) 
MODE OF DELIVERY  
Natural Vaginal Delivery 56% (n=9) 
Caesarean Section 44% (n=7) 
MEAN WEIGHT (grams) 2821 +/- 340 (n=16) 
MEAN LENGTH (cm) 47.8 +/- 1.5 (n=12) 
MEAN HEAD CIRCUMFERENCE (cm) 34.9 (n=16) 
MEAN 1 MINUTE APGAR SCORE 7.8 +/- 1.5 (n=13) 
MEAN 5 MINUTE APGAR SCORE 9.4 +/- 0.7 (n=13) 
REFERRAL ROUTE   
In Hospital (CHBH) 53% (n=8) 
Peripheral Hospital Referral 47% (n=7) 
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APGAR score at 1 minute for neonates born with MMCs via natural vaginal delivery 
(NVD) was compared to neonates born via caesarean section (C-section) in Table 
3.2.  There was no statistically significant difference with a p Value of 0.095. 
 
Table 3.2: Unpaired student t test comparing APGAR scores at 1 minute for 
neonates born via NVD vs. C-section 
GROUP NVD C-Section 
Mean 1 minute APGAR 7 8.4 
Standard Deviation 1.9 0.8 
Standard Error of the Mean 0.8 0,3 
N 6 7 
 
 
APGAR score at 5 minute for neonates born with MMCs via NVD was compared to 
neonates born via C-section in Table 3.3.  There was no statistically significant 
difference with a p Value of 0.48. 
 
Table 3.3: Unpaired student t test comparing APGAR score at 5 minutes for 
neonates born via NVD vs. C-section 
GROUP NVD C-Section 
Mean 1 minute APGAR 9.2 9.4 
Standard Deviation 0.4 0.8 
Standard Error of the Mean 0.2 0,3 
N 6 7 
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 3.3 MMC Characteristics 
Characteristics related to the presenting MMCs of the infants involved in the study 
are summarised in Table 3.4.   
The smallest MMC had a surface area of 3 cm2 and the largest had a surface area 
of 36 cm2.  Surface are was approximated by multiplying the height by width of 
the MMC 
 
Table 3.4: MMC Characteristics  
VARIABLE RESULT 
MMC REGION  
Cervical 0% (n=0) 
Thoracic 4% (n=1) 
 Lumbar 58% (n=14) 
 Sacral 38% (n=9) 
MEAN MMC SURFACE AREA (cm2) 19.4 +/- 9.7 (n=9) 
CSF LEAK ON PRESENTATION    
Yes   50% (n=9) 
 No  50% (n=9) 
KYPHOTIC DEFORMITY   
 Yes  33.33% (n=6) 
 No  66.67% (n=12) 
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 3.4 Associated Neurological Abnormalities    
Neurological abnormalities that were present in the neonates with MMCs in this 
series are summarised in Table 3.5.  Chiari II malformation and hydrocephalus were 
diagnosed with the use of neuroimaging. 
 
Table 3.5: Associated Neurological Abnormalities  
VARIABLE RESULT 
LOWER LIMB NEUROLOGY  
Lower Limbs Intact 29% (n=5) 
 No Movement below Ankle 0% (n=0) 
No Movement below Knee 12% (n=2) 
No Movement below Hip  6% (n=1) 
Complete Paralysis 53% (n=9) 
CLINICAL ASPIRATION/DYSPHAGIA  
 Yes  13%(n=2) 
 No  87% (n=15) 
RADIOLOGICAL CHIARI TYPE II 
MALFORMATION  
  
Yes   94% (n=16) 
No 6% (n=1) 
HYDROCEPHALUS   
Yes   54% (n=13) 
 No 46% (n=11) 
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 3.5 Associated Non-Neurological Abnormalities    
Non-neurological abnormalities that were present in the neonates with MMCs in 
this series are summarised in Table 3.6.   
There were two cutaneous abnormalities in the series and both were located over 
the lower back in the vicinity of the MMC; one was a capillary haemangioma and 
the other was a fawn’s tail – a hairy patch.  
Other congenital abnormalities that were identified within the series were a 
horseshoe kidney in one infant and rectal prolapse in another infant.  One 
neonate also had bilateral femur fractures. 
 
 
Table 3.6: Associated Non-neurological Abnormalities  
VARIABLE RESULT 
CLUBFOOT  
Yes 71% (n=12) 
No 29% (n=5) 
CONGENITAL HIP DYSPLASIA  
 Yes  24%(n=4) 
 No  76% (n=13) 
NEUROGENIC BLADDER    
Yes   41% (n=7) 
No 59% (n=10) 
CUTANEOUS ABNORMALITY   
Yes   12% (n=2) 
 No 88% (n=15) 
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 3.6 Timing to MMC Repair 
Timing to surgery is presented in Table 3.7 and a frequency distribution in relation to 
timing intervals to surgery is presented in Figure 3.1 
 
Table 3.7: Timing to MMC Repair  
VARIABLE RESULT 
MEAN TIMING TO MMC REPAIR 13.6 +/-11.2 (n=24) 
MEDIAN TIMING TO MMC REPAIR 11 
 
 
Figure 3.1: Frequency Distribution in relation to days from birth until MMC Repair  
       
 
 
 
 
 
 
 
 
 
 
0	1	
2	3	
4	5	
6	7	
8	9	
10	
0-3 Days 4-10 Days 10-20 Days > 20 Days 
	 29 
 3.7 Operative Parameters    
Operative parameters relating to requirement for a local flap for closure, 
perioperative haemoglobin values, requirement for transfusion and intensive care 
unit admission are presented in Table 3.8.   
 Of the 4 flaps presented in Table 3.8, 2 utilised a Limberg flap and 2 a reading 
man flap.  The largest haemoglobin drop between pre-operative and post-
operative values was 5.5 g/dL from 17.5 g/dL to 12 g/dL.  The largest transfusion 
volume was 60 mls of packed red blood cells. 
 
Table 3.8: Operative Parameters 
VARIABLE RESULT 
LOCAL FLAP FOR CLOSURE  
Yes 17% (n=4) 
No 83% (n=20) 
HAEMOGLOBIN   
 Mean Pre-Operative Value (g/dL)  14.3 +/-2.3 (n=18) 
 Mean Post-Operative Value (g/dL)  12.7 +/-2.2 (n=17) 
TRANSFUSION   
Yes   44% (n=4) 
No  56% (n=5) 
Mean Transfusion Volume (ml)  41 +/-13.3 (n=4) 
POST-OPERATIVE INTENSIVE CARE 
UNIT ADMISSION 
 
YES    59% (n=10) 
 No 41% (n=7) 
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 3.8 Post-Operative Course 
Post-operative course in relation to requirement for VP shunt, EVD insertion and 
latex allergy is presented in Table 3.9. 
Two revision VP Shunt procedures were performed. 
 
Table 3.9: Post-Operative Course 
VARIABLE RESULT 
VP SHUNT INSERTION  
Yes 50% (n=12) 
No 50% (n=12) 
EVD INSERTION  
Yes 9% (n=2) 
No 91% (n=22) 
LATEX ALLERGY   
Yes 0% (n=0) 
No 100% (n=24) 
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 3.9 Post-Operative Complications    
Post-operative complications arising in the current series under investigation are 
presented in Table 3.10.   
Of the 6 infections that arose, 5 were CSF infections and 1 was a superficial wound 
infection 
All 3 of the patients with a CSF leak went on to complicate with both a wound 
dehiscence and CSF infection. 
Reoperation to address complications was performed for 2 of the 5 patients with 
wound dehiscence and 2 of 3 the patients with CSF leak. 
There were two mortalities in this case series.  One was in a neonate with a large 
MMC requiring a flap for closure.  There was wound dehiscence and CSF leak with 
subsequent CSF infection and systemic sepsis leading to mortality.  The other 
neonate had episodes of apnoea, stridor, aspiration and dysphagia on a 
background of Chiari Type II malformation and demised secondary to respiratory 
arrest.  
 
Table 3.10: Post-Operative Complications 
VARIABLE RESULT 
WOUND DEHISCENCE  
Yes 21% (n=5) 
No 79% (n=19) 
CSF LEAK   
Yes 12.5% (n=3) 
No 87.5% (n=21) 
INFECTION   
Yes   25% (n=6) 
No  75% (n=18) 
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 3.10 Maternal Parameters 
Maternal HIV infection status and pregnancy antiepileptic use are presented in 
Table 3.11.  
Four of the five mothers with HIV were aware of their status prior to pregnancy and 
one was diagnosed following birth of her child.  
Both mothers on anti-epileptics were on sodium valproate. 
 
Table 3.11: Maternal Parameters 
VARIABLE RESULT 
HIV INFECTION  
Yes 29% (n=5) 
No 71% (n=12) 
PREGNANCY ANTIEPILEPTIC USE  
Yes 11% (n=2) 
No 89% (n=16) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 33 
 3.11 Factors Influencing Complication Outcomes 
  3.11.1 Wound Dehiscence and Gestation Period 
Wound dehiscence in relation to gestation period was compared in Table 3.12.  
There was no statistically significant difference with a p Value of 0.58. 
 
Table 3.12: Unpaired student t test comparing gestation period for patients 
with wound dehiscence vs. patients without wound dehiscence 
GROUP Dehiscence  No Dehiscence 
Mean gestation period (weeks) 37.8 38.3 
Standard Deviation 1.5 1.6 
Standard Error of the Mean 0.8 0.5 
N 4 11 
 
 
 
  3.11.2 Wound Dehiscence and Birth Weight 
Wound dehiscence in relation to birth weight was compared in Table 3.13.  There 
was no statistically significant difference with a p Value of 0.10. 
 
Table 3.13: Unpaired student t test comparing birth weight for patients with 
wound dehiscence vs. patients without wound dehiscence 
GROUP Dehiscence  No Dehiscence 
Mean birth weight (grams) 3078.8 2740.0 
Standard Deviation 381.7 307.4 
Standard Error of the Mean 190.9 92.7 
N 4 11 
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  3.11.3 Wound Dehiscence and Maternal HIV status 
Wound dehiscence in relation to maternal HIV status was compared in Table 3.14.  
There was no statistically significant difference with a p Value of 0.54. 
 
Table 3.14: Fischer’s exact test comparing maternal HIV status to wound 
dehiscence. 
GROUP Dehiscence No Dehiscence Total 
HIV Positive 2 3 5 
HIV Negative 2 10 12 
Total 4 13 17 
 
 
 
  3.11.4 CSF Infection and Time to Surgery 
Presence of CSF infection in relation to timing to MMC repair was compared in 
Table 3.15.  There was no statistically significant difference with a p Value of 0.15. 
 
Table 3.15: Unpaired student t test comparing timing to surgery for patients 
with CSF Infection vs. patients without CSF infection 
GROUP  CSF Infection  No CSF Infection 
Mean days to surgery 16.4 10.8 
Standard Deviation 9.4 7.0 
Standard Error of the Mean 4.2 1.6 
N 5 19 
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  3.11.5 CSF Infection and Gestation Period 
CSF infection in relation to gestation period was compared in Table 3.16.  There 
was no statistically significant difference with a p Value of 0.87. 
 
Table 3.16: Unpaired student t test comparing gestation period for patients 
with CSF Infection vs. patients without CSF infection 
GROUP CSF Infection  No CSF Infection 
Mean gestation period (weeks) 38.3 38.1 
Standard Deviation 1.5 1.6 
Standard Error of the Mean 0.8 0.5 
N 4 11 
 
   
 
  3.11.6 CSF infection and Birth Weight 
Presence of CSF infection in relation to birth weight was compared in Table 3.17.  
There was no statistically significant difference with a p Value of 0.76. 
 
Table 3.17: Unpaired student t test comparing birth weight for patients with CSF 
Infection vs. patients without CSF infection 
GROUP  CSF Infection  No CSF Infection 
Mean birth weight (grams) 2775 2837.5 
Standard Deviation 246.0 374.5 
Standard Error of the Mean 123.0 108.1 
N 4 12 
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  3.11.7 CSF Infection and Maternal HIV status 
Presence of CSF infection in relation to maternal HIV status was compared in Table 
3.18.  There was no statistically significant difference with a p Value of 0.11. 
 
Table 3.18: Fischer’s exact test comparing maternal HIV status to CSF 
Infection. 
GROUP CSF Infection No CSF Infection Total 
HIV Positive 3 2 5 
HIV Negative 2 10 12 
Total 5 12 17 
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4. DISCUSSION 
 4.1 Study Sample 
By international standards, the current study was not a very large series of cases – 
24 in total.34-36  However, the patients within the series were operated upon by a 
single surgeon.  When analysing outcomes, this removes the confounding factor of 
surgical technique variation, which may arise, when multiple surgeons operate 
upon patients within a single series.   
In comparing this series to the reported literature, it becomes clear that CHBH has 
a reasonable volume of MMC presentations.  For instance, in the series by Mirzai et 
al. from Turkey, they reported on 190 MMC repairs over a 15 year period, which 
equates to about 12 per year.36   When one considers the MOMS trial, which was a 
multicentre trial between three centres, there were 183 patients included in the 
trial from February 2003 to December 2010.32  Although one must consider 
exclusion criteria, the MOMS numbers would equate to about 8 MMC repair 
operations per centre per year.  The current series under investigation has a rate of 
about 15 MMC presentations requiring surgery per year.  This number is actually 
higher if one also considers the MMCs that presented after the neonatal period 
that were not operated upon at the neonatal unit at CHBH and therefore not 
included in this series.  These patients were operated upon by different surgeons 
and not by the author. 
Unfortunately, given the retrospective nature of this study, a lot of the patients had 
incomplete data for the variables under investigation.  This is limiting in terms of 
data extrapolation and restricts some of the conclusions that may be drawn from 
the discussion that will follow.  This limitation will be discussed further – see section 
4.12. 
 
 4.2 Demographic and Birthing Details 
Demographic analysis of the series reveals that the mean gestation of 38.13 weeks 
was within normal limits and over the 37 week mark, which defines pre-term 
labour.55  Gender distribution was skewed toward male neonates at 66.67%, which 
may have been the result of a small series and is not inline with the reported 
female preponderance. Timson analysed 3521 cases of MMCs and found female 
predilection for the condition at 65.5%.56   
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Unfortunately, the majority of births were via NVD at 56% and not via C-section.  
This is in line with the predominantly postnatal as opposed to prenatal diagnosis of 
MMCs in South Africa.29   
Analysis of the MMC cohort’s mean weight, mean length and mean head 
circumference revealed that the means were within normal range for neonates.57  
APGAR scores at both 1 minute and 5 minutes were also within normal range, with 
mean scores of 7.8 and 9.4 respectively.  When comparison was made between 
APGAR scores for neonates born via NVD vs. neonates born via C-section, it 
appeared that APGAR scores were better at one minute for neonates born via C-
section as opposed to NVD.  The difference was a mean APGAR score of 8.4 as 
opposed to 7; however, this was not statistically significant with a p value of 0.095.  
The difference in APGAR score was negligible by 5 minutes.  These results, although 
not significant, potentially highlight the importance of a planned C-section for 
neonates born with MMCs. 
In regard to MMC referral patterns to CHBH, referrals from peripheral hospitals 
accounted for almost half of the MMCs operated upon at CHBH. 
 
 4.3 MMC Characteristics 
The majority of MMCs in this series were located in the lumbar region, with a 
frequency of 58%.  This is comparable to the series by Mirzai et al. from Turkey who 
had a similar frequency for the lumbar region at 59.5%.36  Following the lumbar 
region, the sacral region was the second most common area in the current series 
and there was only one thoracic MMC.  There were no cervical MMCs in this series, 
which correlates with the relatively low frequency of MMCs at this region.58,59   
Location was based largely on clinical observation, with few of the neonates 
having had a spinal MRI. This was the result of resource restraints at CHBH.  It was 
deemed that an MRI was not essential to proceed with MMC repair surgery and 
waiting for an MRI led to unnecessary delays in the treatment of these neonates.  
As a result, it is possible that some of the MMCs classified as lumbar may have 
been sacral in nature if imaged with MRI. 
Based on the data that was available (n=9), the mean surface area of MMCs in 
this series was 19.4 cm2.  This is somewhat smaller than surface area means 
reported in other series.   Idowu and Apemiye from Nigeria had a mean MMC 
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surface area of 26.4 cm2 in their operative series and Lee et al. from Korea had a 
mean MMC surface are of 47 cm2. 
CSF leak at birth was present in 50% of neonates in this series.  In comparison to the 
series by Sattar et al. from Pakistan this is quite a high rate.62  Sattar et al. reported 
a rate of 3.8%.62  The high rate may be explained by the low rate of C-section 
delivery in this series leading to birth trauma of the MMC sac via NVD. 
Finally, the rate of kyphosis in the current series was 33.33%.  This is higher than the 
rate of 15% quoted in the literature and is possibly the result of a small sample.63 
 
 4.4 Associated Neurological Abnormalities 
Assessment for lower limb neurological deficits revealed that 71% of neonates had 
lower limb deficits and only 29% were intact.  In comparison, Sattar et al. from 
Pakistan had a 46% rate of intact neurology.62  Interestingly, a study by Bartonek 
and Saraste from Sweden, analysing neurological outcome in 56 children born 
with MMCs found only 3 children that were completely intact.64  They used two 
classifications to asses neurological function, that by Sharrard65 and that by Smith 
and Smith66.  These are both detailed classifications that can pick up subtle 
deficits.  Perhaps, application of these scales would have revealed a lower 
percentage of completely intact children. 
Lower brainstem dysfunction presenting as aspiration and/or dysphagia was 
present in 13% of the series and Chiari type II malformation was identified 
radiologically, via CT or MRI, in the majority of patients, at 94%.  These numbers are 
in line with the literature, whereby Chiari Type II malformation is present in about 
90% of children with MMC and where about 5% of neonates with Chiari 
Malformation suffer from lower cranial nerve dysfunction.4,67  Importantly, one of 
the two children suffering from lower cranial nerve dysfunction within the series 
demised secondary to respiratory failure. 
The rate of hydrocephalus within the series at 54% was low.  This is below the 80-
90% rate of hydrocephalus quoted within the general literature.12  The reason is 
potentially multifactorial, with the small size of the series being a strong factor.  
However, the strategy in the current study of repairing the MMC and only VP 
shunting if hydrocephalus arose may have decreased the requirement for VP 
shunting and thereby the associated diagnosis of hydrocephalus.  Alternatively, 
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follow-up was undertaken until the newborns were discharged and therefore some 
of the discharged neonates may have represented with hydrocephalus.  Although 
this would have led to underreporting, the author is not aware of any such cases 
within this current series.  In addressing the need to accurately predict which 
neonates born with MMCs develop hydrocephalus Phillips et al. studied various 
parameters in search of useful predictors.68  They found that head circumference 
velocity greater than 0.32cm/day, head ultrasonography mean ventricular index 
of 2.33cm and mean thalamo-occipital distance of 4.04cm were associated with 
development of hydrocephalus.68  By using these parameters, the authors 
commented that it is possible to identify which neonates born with MMCs require 
CSF diversion and thereby shorten the period of watchful waiting and which 
neonates do not require CSF diversion and thereby avoid unnecessary 
procedures.68 
 
 4.5 Associated Non-neurological Abnormalities 
Analysis of associated non-neurological abnormalities revealed that 71% of the 
neonates in the series had associated clubfoot deformity.  This prevalence was 
higher than the 30-50% prevalence reported by Swaroop and Dias.69  The 
prevalence of congenital hip dysplasia in the current series was lower than 
clubfoot at 24%.  This is lower than the 30-50% prevalence quoted by Westcott et 
al.70  Evidence of clinically manifested neurogenic bladder was present in 82% of 
the neonates examined in this series.  This result is inline with the expected high 
prevalence of neurogenic bladder in neonates born with MMCs.29 Finally, 
cutaneous abnormality was present in 12% of neonates within the series – These 
abnormalities included hyperpigmentation and/or hypertrichosis(faun’s tail).  This is 
inline with their relatively low prevalence.3 
 
 4.6 Timing to MMC Repair 
Mean time to MMC repair was 13.6 days, median was 11 days and only 5 of the 24 
cases were operated upon at less than 72 hours, which is the generally accepted 
gold standard;23 although, as addressed in the introduction, some authors have 
pushed for time zero repair.33  This less than desirable timing is the result of multiple 
factors.  Delayed referrals, transfer from peripheral hospitals to CHBH (47% in this 
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series) and availability of the operating theatre were all systemic factors that 
delayed repair times.  Delay based on medical grounds, for medical optimisation 
prior to surgery, was not a common reason for delays.  Unfortunately, in the current 
series there were 4 neonates that were repaired beyond 20 days, which increased 
the standard deviation to 11.2 days and also increased the aforementioned 
mean. 
Although timing to repair in the current series is not ideal it is interesting to note that 
Atenello et al. from the United States reported on MMC repair timing based on 
countrywide databases.41  They found that 19% of MMC repairs occur outside the 
48 hour mark.  Their results in regard to timing are much better than the results from 
the current series, however they do demonstrate that even in a highly developed 
setting it is not easy to repair all MMCs within the first few days of life.  For 
comparison, Idowu and Apemiye in their series from Nigeria commented that the 
majority of patients were operated upon after 7 days of life and Sattar et al. from 
Pakistan reported that their average age of repair was 4 weeks.60,62 
 
 4.7 Operative Parameters 
Closure of large MMC defects is potentially challenging and requires Plastic 
Surgery techniques that utilise flaps for closure.23  In the current series, 17% required 
closure with a flap.  This is lower than that reported in other series.  Kemaloğlu et al. 
reported a 40% rate of closure requiring flaps.71  However, the mean MMC surface 
area reported in this series is somewhat smaller than that reported in other series – 
see Section 4.3.  This may account for the smaller percentage of flap utilisation in 
the current series.  Of note there was one flap breakdown; however this child had 
an extensive myelomeningocoele. 
Data in regard to mean pre-operative and post-operative haemoglobin levels 
and the need for transfusion revealed a drop in mean haemoglobin following 
surgery.  However the drop was modest at 1.6g/dL.  Transfusion was required for 
44% of neonates, however this percentage was derived from only 9 patients of the 
series total of 24.  To the author’s knowledge, there are no other series that have 
documented mean haemoglobin values for comparative analysis. 
Post-operative admission was most frequently at the neonatal intensive care unit 
as opposed to the high care unit – 59% vs. 41%.  For the majority of neonates, 
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discharge from the intensive care unit occurred on the following post-operative 
day. 
 4.8 Post-Operative Course 
Post MMC repair 12 patients had a VP shunt inserted and 2 patients had an EVD 
inserted.  Comparatively, 13 patients had hydrocephalus.  The two patients that 
had an EVD inserted had concomitant CSF infection with their hydrocephalus and 
the EVD was used as a temporising measure.  Of the two patients with the EVD, 
one survived and went on to have a VP shunt inserted and thereby the total 
number of VP shunts in the series was 12.  The other patient was one of the two 
mortalities in the series and never had a VP shunt inserted – see Section 3.9.  Follow 
up was up until 01 January 2016. 
There was no documented latex allergy.  Although an effort was made to avoid 
latex products in these patients, this policy was not strictly adhered to.  
Interestingly, although the incidence of latex allergy in MMC patients is thought to 
by high, a study from Cape Town also found a low incidence.72  Their rate of latex 
allergy was 16.7%.72 
 
 4.9 Post-Operative Complications 
Within the current series there was a 21% rate of wound dehiscence.  This 
amounted to 5 cases of which the dehiscence in 3 of the patients was minor, with 
skin edge necrosis that was treated conservatively.  If this is taken into account the 
rate is modified to 8.3%.  Comparatively, Chand et al. had a wound dehiscence 
rate of 5.4% and Lee et al. had a rate of 10%.39,61 
CSF leak rate within the series was at 12.5%.  This is inline with other series.  Chand et 
al. had a CSF leak rate of 8.1% and Fazal et al. had a CSF leak rate of 12.5%.39,40 
Infection occurred in 25% of the patients within the series. Of the 6 infections within 
the series 5 were CSF infections, giving the series a CSF infection rate of 21%.  This is 
a high rate.  Comparatively, Demir et al. had a CSF infection rate of 16.4%, 
Attenello et al. in their nation-wide United States study had an 18% infection rate 
and Narotam et al. from Durban had an infection rate of 14.8%.41,42,50 
As expected, the three patients that had a CSF leak went onto also complicate 
with wound dehiscence and CSF infection.  This is well recognised and has been 
reported in other operative MMC series as well.38,61,73 
	 43 
 4.10 Maternal Parameters 
With prevalence of HIV in Soweto being potentially as high as 30%, HIV prevalence 
in mothers giving birth to neonates with MMCs was investigated.79  In line with this, 
29% of mothers had HIV in this series.  If the observation of CSF infection being 
more common in neonates born to mothers with HIV stands – see Section 3.11.7, 
identifying neonates born to mothers with HIV is clinically significant. 
Finally, two mothers within the series were using sodium valproate as an epileptic 
treatment during their pregnancy.  This is likely to be reflective of problems with 
patient education on perinatal anti-epileptics use and is an extension of a known 
underlying theme of poor maternal awareness of perinatal MMC risk factors in sub-
Saharan Africa.48,49 
 
 4.11 Factors Influencing Complication Outcomes 
With the aim of gaining insight into potential reasons behind the complications 
within the series, variables of interest were analysed for statistical significance.  
Unfortunately, the small number of patients within the series made attainment of 
statistical significance difficult; however, some trends did emerge.  
 
  4.11.1 Wound Dehiscence and Gestation Period 
Based on reasoning that neonates born at an earlier gestation period may have 
been less developed and this may have impacted on wound healing, a 
comparison was made between infants with dehiscence and those without 
dehiscence to see if the neonates with dehiscence were born earlier.  Although 
the mean gestational period for neonates with dehiscence was slightly less at 37.8 
weeks as opposed to 38.3 weeks for the non-dehiscence group this was not 
statistically significant with a p Vale of 0.58.   
 
  4.11.2 Wound Dehiscence and Birth Weight 
On the assumption that neonates born with a low birth weight might be at higher 
risk of wound dehiscence due to their smaller size, birth weight comparison 
between infants with dehiscence and those without dehiscence was investigated.  
Interestingly, neonates with dehiscence were actually born heavier than the 
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neonates without dehiscence with mean birth weights of 3078.8 grams and 2740.0 
grams respectively.  This was not statistically significant with a p Value of 0.10.   
 
  4.11.3 Wound Dehiscence and Maternal HIV Status 
There is limited evidence that patients with HIV may have delayed healing 
capacity.74,75  Interestingly, there is also evidence that neonates born to mothers 
with HIV have lower antibody responses when compared to neonates born to 
mothers without HIV.76  As wound healing is based on an inflammatory response, 
which utilises components of the immune system, it was of interest to evaluate 
wound dehiscence rates between neonates born to HIV infected mothers and 
those born to non-infected mothers.  Following statistical analysis however, wound 
dehiscence did not appear to correlate with maternal HIV infection status – p 
Value was 0.54. 
 
  4.11.4 CSF Infection and Time to surgery 
The correlation between delayed MMC repair and subsequent infection is well 
established and has been discussed elsewhere – see Section 1.7.2.4.  As such, an 
analysis of timing to surgery between neonates with CSF infection and neonates 
without CSF infection was undertaken.  Mean days to surgery for the CSF infected 
group was 16.4 days, whereas mean days to surgery for the non-CSF infected 
group was 10.8.  Although the p Value of 0.15 was not significant, it would be 
expected that with a larger study sample, the p Value would veer towards 
significance. 
 
  4.11.5 CSF Infection and Gestation Period 
Premature infants have reduced immunity.77 Based on this premise gestational 
period was compared between infants with CSF infection and infants without CSF 
infection.  There was no difference in mean gestation period between the two 
groups, with the CSF infection group having a mean gestation period of 38.3 
weeks and the non-CSF infection group having a mean gestation period of 38.1 
weeks.  The p Value was 0.87 and not significant. 
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  4.11.6 CSF Infection and Birth Weight 
On evidence that low birth weight can lead to impaired immunity, birth weights 
were compared between infants with CSF infection and infants without CSF 
infection.78  Birth weight for infants with CSF infection was slightly lower at 2775 
grams as opposed to 2837.5 grams for the non-infected group; however, this was 
not significant with a p Value of 0.76. 
 
  4.11.7 CSF Infection and Maternal HIV status 
Based on the aforementioned evidence that neonates born to mothers with HIV 
have lower antibody responses when compared to infants born to mothers without 
HIV, correlation between maternal HIV status and CSF infection was investigated.76  
Although the series cohort was small, p Value was approaching significance at 
0.11 in support of higher infection incidence in MMC neonates born to mothers 
with HIV.  This might be due to impaired passive neonatal immunity and warrants 
further investigation with a larger study size. 
 
 4.12 Limitations 
The small sample size of 24 patients in the current series limits statistical tests aiming 
to compare parameters of interest. Future studies expanding on the current series 
would likely achieve more meaningful data by increasing the cohort number.   
As the study is retrospective, data collection for a lot of the parameters was 
incomplete.  This led to many of the parameters of interest not having data 
equivalent to 24 patients, which was the complete patient number in this series.  
Again, this limits data interpretation.  A prospective study design would greatly 
assist with this limitation. 
The author reviewed all of the files, which had information pertaining to the 
author’s post-operative results.  This could potentially lead to bias in result 
reporting.  
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 4.12 Conclusion 
To the author’s knowledge, this is the first surgical series from South Africa to 
analyse post-operative MMC repair results.  This is important, as unique resource 
related challenges faced both in a South African and Sub-Saharan African 
context have been probed.  This series also provides vital information on the 
standard of care provided for neonates born with MMCs at CHBH and will aid in 
Improving care for these patients.  
The series reported on a total of 24 neonates that were born with MMCs and 
operated upon by a single surgeon at CHBH.  Mean gestation was 38.13 weeks, 
the majority of neonates were male at 66.67% and 56% were born via NVD.   Mean 
weight, length and head circumference were within normal limits and mean 
APGAR scores at 1 and 5 minutes were 7.8 and 9.4 respectively.  Referral route to 
Neurosurgery services was almost equal between in-hospital referral at 53% and 
peripheral hospital referral at 47%. 
The majority of MMCs in this series were in the lumbosacral region and mean 
surface area was 19.4cm2.  CSF leak was present in 50% of patients on presentation 
and kyphotic deformity was present in 33.33%.  Neurologically, 71% of neonates 
had lower limb neurology, 13% had evidence of lower cranial nerve dysfunction 
and 54% had hydrocephalus.  Chiari Type II malformation was present 
radiologically in 94% of neonates.  Analysis of non-neurological abnormalities 
revealed prevalence of clubfoot at 71%, congenital hip dysplasia at 24%, 
neurogenic bladder at 82% and cutaneous abnormalities at 12%. 
Mean time from birth to MMC repair was 13.6 days with only 5 out of 24 neonates 
repaired within 72 hours.  The majority of neonates (59%) were admitted to 
intensive care post-operatively.  Closure wise, 17% required a flap to close the 
defect.  Mean preopeative haemoglobin was 14.3 g/dL and this dropped to a 
mean of 12.7 g/dL postoperatively.  Transfusion was initiated in 44% of patients with 
a mean transfusion volume of 41mls. 
Within the series, 46% went on to have a VP shunt inserted and 9% had an EVD.  
Latex allergy was absent. 
Post-operatively there were 2 mortalities in the series, one secondary to Chiari Type 
II malformation and lower cranial nerve dysfunction and the other was due to 
sepsis.  Complication wise, wound dehiscence arose in 21% of neonates, CSF leak 
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in 12.5% and infection in 25%.  Of note, of the three patients with CSF leak, all three 
went on to have wound dehiscence and CSF infection. 
Evaluation of maternal parameters within the series revealed 28% were HIV positive 
and 11% used anti-epileptics during their pregnancy. 
On analysis of factors influencing complications there was no statistical 
significance between wound dehiscence and gestation period, wound 
dehiscence and birth weight, wound dehiscence and maternal HIV status, CSF 
infection and gestation period and CSF infection and birth weight.  Although not 
statistically significant, results trended toward significance for CSF infection and 
increased time to MMC repair surgery and CSF infection and birth to a HIV positive 
mother.  The potential correlation between CSF infection post MMC repair and 
birth to a HIV positive mother has not been reported previously. 
Following these results, it is apparent that CHBH treats a relatively high volume of 
neonates born with MMCs.  It is also clear that the time period between birth of 
these neonates and repair of their MMC needs to be reduced.  This study may 
have also identified that neonates born to mothers with HIV are at higher risk for 
CSF infection postoperatively.   Based on these insights, a further prospective study 
collecting variables of interest in relation to MMC patients, maternal HIV status and 
their treatment is recommended, especially if this is combined with an active 
protocol that aims to repair all neonates born with MMCs within 72 hours.  Such a 
study could compare complication rates based on a 72-hour repair strategy to the 
current study and investigate if such a protocol improves outcomes.  Ultimately, 
further work in this area will improve patient care for neonates born with MMCs at 
CHBH. 
 
 
 
 
 
 
 
 
 
	 48 
5. REFERENCES 
1. Copp AJ, Greene ND. Neural tube defects – disorders of neurulation and 
related embryonic processes. Wiley Interdiscip Rev Dev Biol. 2013;2:213-227. 
2. Mitchell LE. Epidemiology of neural tube defects. Am J Med Genet C Semin 
Med Genet. 2005;135:88–94. 
3. Dias M, Partington M. Congenital Brain and Spinal Cord Malformations and 
Their Associated Cutaneous Markers. Pediatrics. 2015;136(4):e1105-1119. 
4. Copp AJ, Adzick NS, Chitty LS, Fletcher JM, Holmbeck GN, Shaw GM.  Spina 
bifida. Nat Rev Dis Primers. 2015;4(1):15007. 
5. Dias MS. Neurosurgical management of myelomeningocele (spina bifida). 
Pediatr Rev. 2005;26(2):50-60. 
6. Alsdorf R, Wyszynski DF. Teratogenicity of sodium valproate. Expert Opin Drug 
Saf. 2005;4(2):345-353. 
7. Hahn YS. Open myelomeningocele. Neurosurg Clin N Am. 1995;6(2):231-241. 
8. Catala M. Embryology applied to neural tube defects (NTDs) In: Özek M, 
Cinalli G, Maixner W, eds. Spina bifida: management and outcome. Milan: 
Springer; 2008. 
9. Sav A. Pathological Anatomy of Spina Bifida In: Özek M, Cinalli G, Maixner 
W, eds. Spina bifida: management and outcome. Milan: Springer; 2008. 
10. Kit SA, Hope N. Genetic Complexity of Human Myelomeningocele. Genetics. 
2013; 2(1):116-118. 
11. Dorsher PT, McIntosh PM. Neurogenic bladder. Adv Urol. 2012;2012:816274. 
12. Cinalli G, Spennato P, Buonocore MC, Cianciulli E, Vinchon M, Sgouros S. 
Pathophysiology of hydrocephalus In: Özek M, Cinalli G, Maixner W, eds. 
Spina bifida: management and outcome. Milan: Springer; 2008. 
13. Niazi T, Walker ML. Myelomeningocele and medical ethics In: Özek M, Cinalli 
G, Maixner W, eds. Spina bifida: management and outcome. Milan: 
Springer; 2008. 
14. McLone DG, Czyzewski D, Raimondi AJ, Sommers RC. Central nervous 
system infections as a limiting factor in the intelligence of children with 
myelomenigocele. Pediatrics. 1982;70(3):338-342. 
15. Pruitt LJ. Living with spina bifida: a historical perspective. Pediatrics. 
2012;130(2):181-183. 
	 49 
16. Milunsky A, Jick SS, Bruell CL, MacLaughlin DS, Tsung YK, Jick H, et al. 
Predictive values, relative risks, and overall benefits of high and low maternal 
serum alpha-fetoprotein screening in singleton pregnancies: new 
epidemiologic data. Am J Obstet Gynecol. 1989;161(2):291-297. 
17. Wilson RD, Audibert F, Brock JA, Campagnolo C, Carroll J, Cartier L, et al. 
Prenatal screening, diagnosis, and pregnancy management of fetal neural 
tube defects. J Obstet Gynaecol Can. 2014; 36(10) 927-942. 
18. Coleman BG, Langer JE, Horii SC. The diagnostic features of spina bifida: the 
role of ultrasound. Fetal Diagn Ther. 2015;37:179-196. 
19. Mirsky DM, Schwartz ES, Zarnow DM. Diagnostic features of 
myelomeningocele: the role of ultrafast fetal MRI. Fetal Diagn Ther. 
2015;37:219-225. 
20. Chitayat D, Matsui D, Amitai Y, Kennedy D, Vohra S, Rieder M et al. Folic 
acid supplementation for pregnant women and those planning pregnancy: 
2015 update. The Journal of Clinical Pharmacology. 2016;56(2):170-175. 
21. MRC Vitamin Study Research Group. Prevention of neural tube defects: 
results of the medical research council vitamin study. Lancet. 
1991;338(8760):131-137. 
22. Czeizel AE, Dudas I. Prevention of the first occurrence of neural- tube 
defects by periconceptional vitamin supplementation. N Engl J Med. 
1992;327(26):1832–1835.  
23. McLone DG. Closure of the myelomeningocele In: Goodrich JT ed. 
Neurosurgical operative atlas pediatric neurosurgery. New York: Thieme 
Medical Publishers Inc; 2008. 
24. Miller PD, Pollack IF, Pang D, Albright AL. Comparison of simultaneous versus 
delayed ventriculoperitoneal shunt insertion in children undergoing 
myelomeningocele repair. J Child Neurol. 1996;11(5):370-372. 
25. Warf BC. Hydrocephalus associated with neural tube defects: 
characteristics, management, and outcome in sub-Saharan Africa. Childs 
Nerv Syst. 2011;27(10):1589-1594. 
26. Bowman RM, McLone DG, Grant JA, Tomita T, Ito JA. Spina bifida outcome: 
a 25-year perspective. Pediatr. Neurosurg. 2001;34(3):114-120. 
	 50 
27. Baykan N. Anesthesiology of the newborn with spina bifida In: Özek M, Cinalli 
G, Maixner W, eds. Spina bifida: management and outcome. Milan: 
Springer; 2008. 
28. Albright AL, Okechi H. Distal cordectomies as treatment for lumbosacral 
myelomeningoceles. J Neurosurg Pediatr. 2014;13(2):192-195. 
29. Fieggen G, Fieggen K, Stewart C, Padayachy L, Lazarus J, Donald K et al. 
Spina bifida: a multidisciplinary perspective on a many-faceted condition. S 
Afr Med J. 2014;104(3):213-217. 
30. Grosse SD, Ouyang L, Collins JS, Green D, Dean JH, Stevenson RE. Economic 
evaluation of a neural tube defect recurrence-prevention program. Am J 
Prev Med. 2008;35:572–577. 
31. Adzick NS. Fetal surgery for myelomeningocele: trials and tribulations. J 
Pediatr Surg. 2012;47(2):273-281. 
32. Adzick NS, Thom EA, Spong CY, Brock JW 3rd, Burrows PK, Johnson MP. A 
randomized trial of prenatal versus postnatal repair of myelomeningocele. N 
Engl J Med. 2011;364(11):993-1004. 
33. Pinto FCG, Matushita H, Furlan ALB, Alho EJ, Goldenberg DC, Bunduki V, et 
al. Surgical treatment of myelomeningocele carried out at ‘time zero’ 
immediately after birth. Pediatr Neurosurg. 2009;45:114-118. 
34. Lorber J. Results of treatment of myelomeningocele. An analysis of 524 
unselected cases with special reference to possible selection for treatment. 
Dev Med Child Neurol. 1971;13:279–303. 
35. McLone DG. Results of treatment of children born with a myelomeningocele. 
Clin Neurosurg. 1983;30:407-412. 
36. Mirzai H, Ersahin Y, Mutluer S, Kayahan A. Outcome of patients with 
meningomyelocele: the Ege university experience. 1998;14(3):120-123. 
37. Özek M. Early surgical complications of spina bifida In: Özek M, Cinalli G, 
Maixner W, eds. Spina bifida: management and outcome. Milan: Springer; 
2008. 
38. Pang D. Surgical complications of open spinal dysraphism. Neurosurg Clin N 
Am. 1995; 6: 243-257. 
39. Chand MB, Agrawal J, Bista P. Anaesthetic challenges and management of 
myelomeningocele repair. Postgrad Med Journ of NAMS. 2011;11(1): 41-46. 
	 51 
40. Fazal G, Mumtaz A, Farooq A. Risks of surgery for myelomeningocele in 
children. Pak. J. of Neurol. Surg. 2016;20(1):53-57. 
41. Attenello F, Tuchman A, Wen T, Nallapa S, Christian E, Cen SY, et al. Infection 
rates following prolonged time to open neural tube repair: a national study. 
Neurosurgery.2015;62:229. 
42. Demir N, Peker E, Gulsen I, Agengin K, Tuncer O. Factors affecting infection 
development after myelomeningocele repair in newborns and the efficacy 
of antibiotic prophylaxis. Childs Nerv Syst. 2015;31:1355-1359. 
43. Bowman RM, McLone DG. Neurosurgical management of spina bifida: 
research issues. Dev Disabil Res Rev. 2010;16:82-87. 
44. Buccimazza SS, Molteno CD, Dunne TT, Viljoen DL. Prevalence of neural tube 
defects in Cape Town, South Africa. Teratology. 1994;50(3):194-199. 
45. Teckie G, Krause A, Kromberg JG. Neural tube defects in Gauteng, South 
Africa: recurrence risks and associated factors. S Afr Med J. 2013;103(12):973-
977. 
46. Lebese V, Aldous C, Malherbe HL. South African congenital disorders data, 
2006-2014. S Afr Med J. 2016;106(10):992-995. 
47. Sayed AR, Bourne D, Pattinson R, Nixon M, Henderson B. Decline in the 
prevalence of neural tube defects following folic acid fortification and its 
cost-benefit in South Africa. Birth Defects Res A Clin Mol Teratol. 
2008;82(4):211-216. 
48. Adeleye AO, Joel-Medewase VI. Awareness and uptake of measures for 
preventing CNS birth defects among mothers of affected children in a sub-
Saharan African neurosurgeon’s practice. Childs Nerv Syst. 2015;31(12):2311-
2317. 
49. Sayed AR, Nixon J, Bourne DE. Folic acid awareness among women of 
reproductive age in Cape Town. S Afr Med J. 2006;96(1):12. 
50. Narotam PK, van Dellen JR, du Trevou MD, Gouws E. Operative sepsis in 
neurosurgery: a method of classifying surgical cases. Neurosurgery. 
1994;34(3):409-415. 
51. Buccimazza S, Molteno C, Dunne T. Pre-school follow-up of a cohort of 
children with myelomeningocele in Cape Town, South Africa. Ann Trop 
Paediatr. 1999;19(3):245-252. 
	 52 
52. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of 
pregnancy: an updated systemic review and meta-analysis. AIDS. 
2011;25(18):2301-2304. 
53. Gilbert SF. Developmental Biology. 7th ed. Sunderland: Sinauer Associates; 
2003:394. 
54. Copp AJ, Adzick NS, Chitty LS, Fletcher JM, Holmbeck GN, Shaw GM.  Spina 
bifida. Nat Rev Dis Primers. 2015;4(1):15007. Figure 2, Neurulation and the 
origin of open and closed spina bifida; p. 35. 
55. Behrman RE, Butler AS. Preterm birth: causes, consequences and prevention. 
Washington D.C.: The National Academies Press; 2007:3. 
56. Timson J. The sex ratio in spina bifida. Genetica. 1969;40(3):427-433. 
57. World Health Organization. The WHO child growth standards (internet). 
Geneva: World Health Organization; 2016 (cited 2016 Nov 8). Available from:  
www.who.int/childgrowth/standards/en/ 
58. Zohreh H, Farideh N, Parvin T, Syed SK, Abdol-Mohammad K. cervical 
myelomeningocele. Neurosurgery. 2006;58(6):1168-1174. 
59. Andronikou S, Wieselthaler N, Fieggen AG. Childs Nerv Syst. 2006;22(4):379-
384. 
60. Idowu OE, Apemiye RA. Outcome of myelomeningocoele repair in sub-
Saharan Africa: the Nigerian experience.  Acta Neurochir (Wien). 
2008;150(9):911-913. 
61. Lee BJ, Sohn MJ, Han SR, Choi CY, Lee DJ, Kang JH. Analysis of risk factors 
and management of cerebrospinal fluid morbidity in the treatment of spinal 
dysraphism. J Korean Neurosurg Soc. 2013;54(3):225-231. 
62. Sattar MH, Shahid A, Rashid J. Management of myelomeningocele. Journal 
of Surgery Pakistan (International). 2008;13(1):7-11. 
63. Özek M, Bulent E, Janichi T. Management of vertebral problems and 
deformities In: Özek M, Cinalli G, Maixner W, eds. Spina bifida: management 
and outcome. Milan: Springer; 2008. 
64. Bartonek A, Saraste H. Factors influencing ambulation in myelomeningocele: 
a cross-sectional study. Dev. Med. Child Neurol. 2001;43:253-260. 
65. Sharrard WJW. The segmental innervation of the lower limb muscles in man. 
Ann Roy Coll Surg. 1964;35:106-122. 
	 53 
66. Smith GK, Smith ED. Selection for treatment in spina bifida cystica. BMJ. 
1973;4:189-197. 
67.  Wharf B. International Federation for Spina Bifida and Hydrocephalus. 
Management protocol for myelomeningocele (internet). Brussels: 
International Federation for Spina Bifida and Hydrocephalus;2008 (cited 2016 
Nov 10). Available from: 
http://www.ifglobal.org/images/management%20protocol%20for%20myelo
meningocele.pdf. 
68. Phillips BC, Gelsomino M, Pownall AL, Ocal E, Albert GW. Predictors of the 
need for cerebrospinal fluid diversion in patients with myelomeningocele. J 
Neurosurg Pediatrics. 2014;14:167-172. 
69. Swaroop VT, Dias L. Orthopaedic management of spina bifida-part II: foot 
and ankle deformities. J Child Orthop. 2011;5(6):403-414. 
70. Westcott MA, Dynes MC, Remer, EM, Donaldson JS, Dias LS. Congenital and 
acquired orthopedic abnormalities in patients with myelomeningocele. 
1992;12(6):1155-1173. 
71. Kemaloğlu CA, Özyazgan İ, Ünverdi ÖF. A decision-making guide for the 
closure of myelomeningocele skin defects with or without primary repair. J 
Neurosurg Pediatr. 2016;18(2):187-191.  
72. Johar A, Lim DL, Arif SA, Hawarden D, Toit GD, Weinberg EG. Low 
prevalence of latex sensitivity in South African spina bifida children in Cape 
Town. Pediatr Allergy Immunol. 2005; 16(2):165-170. 
73. Liu V, Gillis C, Cochrane D, Singhal A, Steinbok P. CSF complications 
following intradural spinal surgeries in children. Childs Nerv Syst. 
2014;30(2):299-305. 
74. Burns J, Pieper B. HIV/AIDS: impact on healing. Ostomy Wound Manage. 
2000;46(3):30-40. 
75. Richardson J, Hill AM, Johnston CJ, McGregor A, Norrish AR Eastwood D. 
Fracture healing in HIV-positive populations. J Bone Joint Surg Br. 
2008;90(8):988-994. 
76. Jones CE, Naidoo S, De Beer C, Esser M, Kampmann B, Hesseling AC. 
Maternal HIV infection and antibody responses against vaccine-
preventable diseases in uninfected infants. JAMA. 2011;305(6):576-584. 
	 54 
77. Sharma AA, Jen R, Butler A, Lavoie PM. The developing human preterm 
neonatal immune system: a case for more research in this area.  Clin 
Immunol. 2012;145(1):61-68. 
78. Chandra RK. Nutrition and immunology: from the clinic to cellular biology 
and back again. Proc Nutr Soc. 1999;58(3):681-683. 
79. Fabian J, Katz I, Gerntholtz T, Goetsch S, Naicker S. Chronic kidney disease in 
human immunodeficiency virus infection.  Panimerva Med. 2007; 49(2):51-66. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 55 
APPENDIX A – DATA COLLECTION SHEET 
 
 
Study Number (De-identified for confidentiality)  
Gestational Age  
Birth Weight  
Gender  
Evidence of CSF Leak Preoperatively  
Administration of Preoperative Antibiotics   
Days to Surgery  
Utilisation of a Flap for Closure  
Hydrocephalus  
Ventriculoperitoneal Shunt Insertion  
Kyphosis  
Size of MMC – Height (Height in millimeters)  
Size of MMC -  Width (Width in millimeters)  
Spinal Region of MMC (Thoracic/Lumbar)  
Blood Transfusion Volume  
Maternal Diabetes  
Maternal HIV Status   
CSF Leak Postoperatively  
Wound Infection  
Meningitis  
Encephalitis  
Operative Wound Dehiscence  
Other  
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